Tempest Therapeutics, Inc. (TPST)
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $295.0K
- Net income
- -$26.3M
- Total assets
- $16.9M
- Market cap
- $18.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$26.6M
- Income tax
- $0
- Net income
- -$26.3M
- EPS (basic)
- $-6.33
- EPS (diluted)
- $-6.33
Balance sheet
- Total assets
- $16.9M
- Current assets
- $8.3M
- Total liabilities
- $10.3M
- Current liabilities
- $3.3M
- Shareholders’ equity
- $6.7M
Cash flow
- Operating cash flow
- -$26.8M
- Investing cash flow
- $22.6M
- Financing cash flow
- $4.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $18.8M
- EPS (diluted)
- $-6.33
- Shares outstanding
- 20.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 28, 2021
Tempest Therapeutics, Inc. (TPST) Stock Price
- Reported a net loss of $26.3M in FY2017.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tempest Therapeutics, Inc..
Write a review
News about Tempest Therapeutics, Inc.
News & sentiment via Polygon.io
Tempest Therapeutics, Inc.: frequently asked questions
Is Tempest Therapeutics, Inc. an American company?
Tempest Therapeutics, Inc. is a US-based company headquartered in Brisbane, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Tempest Therapeutics, Inc. headquartered?
Tempest Therapeutics, Inc. is headquartered in Brisbane, California, United States.
Is Tempest Therapeutics, Inc. publicly traded?
Yes — Tempest Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TPST on the NASDAQ.
What does Tempest Therapeutics, Inc. do?
Tempest Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
